#AAVVectorsForGeneTherapy

[elainaledoyen]

The researchers from Adverum Biotechnologies. (Redwood City, CA) have developed a method for generating eukaryotic cell libraries for screening mutant AAV capsid proteins. Delivering therapeutic drugs via viral vectors is a potential strategy for treating and preventing various human diseases and genetic disorders. Since wild-type AAVs are nonpathogenic and have no etiologic relationship with any known disorders, recombinant vectors based on it are recognized to have great clinical safety. In human clinical trials, AAVs have demonstrated great promise. However, cell tropism (the capacity for viruses to enter and infect cells) and neutralizing antibody (NAb) reactions are the challenges for AAV-based gene therapy. Future studies will require better screening technologies as well as effective anti-immune therapy.